BioSpace News Archive

Genmab A/S and AbbVie announced topline results from the follicular lymphoma cohort of the phase 1/2 EPCORE™ NHL-1 clinical trial evaluating epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously.

Cognition Therapeutics, Inc. announced that it will host a conference call and webcast on June 28, 2023, at 8:00am ET to discuss topline results from its Phase 2 SEQUEL Study for mild-to-moderate Alzheimer’s disease.

ICON plc announced that it will release its financial results for the second quarter 2023 after the market closes on Wednesday, July 26, 2023.

Bayer, a global leader in radiology, has initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane, an investigational extracellular macrocyclic gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI).

Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2023, ended March 31, 2023.

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”) today reported audited financial results for its fiscal year ended March 31, 2023, and recent business highlights.

The Canadian Medical Isotope Ecosystem will support the development, production, advancement and distribution of isotopes, and position Canada as an international medical isotope powerhouse

Reata Pharmaceuticals, Inc. announced that the United States Food and Drug Administration has approved the Prior Approval Supplement to update the drug substance specification for SKYCLARYS®, the first and only FDA approved drug for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.

Axsome Therapeutics, Inc. announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering.

Sihuan Pharmaceutical Holdings Group Ltd. together with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd., a non-wholly owned subsidiary of Company, has received a drug registration approval from the National Medical Products Administration of China of Anaprozole Sodium Enteric-coated Tablet for the treatment of duodenal ulcer.